anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Macrophages are key immune cells that can adapt their metabolic phenotype in response to different stimuli. Lysine deacetylases are important enzymes regulating inflammatory gene expression and lysine deacetylase inhibitors have been shown to exert anti-inflammatory effects in models of chronic obstructive pulmonary disease. We hypothesized that these anti-inflammatory effects may be associated with metabolic changes in macrophages. To validate this hypothesis, we used an unbiased and a targeted proteomic approach to investigate metabolic enzymes, as well as liquid chromatography-mass spectrometry and gas chromatography-mass spectrometry, to quantify metabolites in combination with the measurement of functional parameters in primary murine alveolar-like macrophages after lipopolysaccharide-induced activation in the presence or absence of lysine deacetylase inhibition. We found that lysine deacetylase inhibition resulted in reduced production of inflammatory mediators such as tumor necrosis factor α and interleukin 1β. However, only minor changes in macrophage metabolism were observed, as only one of the lysine deacetylase inhibitors slightly increased mitochondrial respiration while no changes in metabolite levels were seen. However, lysine deacetylase inhibition specifically enhanced expression of proteins involved in ubiquitination, which may be a driver of the anti-inflammatory effects of lysine deacetylase inhibitors. Our data illustrate that a multiomics approach provides novel insights into how macrophages interact with cues from their environment. More detailed studies investigating ubiquitination as a potential driver of lysine deacetylase inhibition will help developing novel anti-inflammatory drugs for difficult-to-treat diseases such as chronic obstructive pulmonary disease.
PURPOSE:An external preparation for the skin useful for remedying and preventing skin diseases such as humid tetter, acne, wound, or protecting the skin as a drug, quasi-drug, or cosmetic, containing dipyruvic triureide. CONSTITUTION:An external preparation for the skin containing dipyruvic triuredie as an active ingredient. The external preparation for the skin has remedy promoting action on damaged parts such as wound, ulcer, burn, etc., astringent action, and covering action. It is useful for remedying erosion of the skin or mucosa, ulcer, and skin diseases such as humid tetter, etc., and used as drug or guasi-drug having the above-mentioned medicinal effects. Since the active ingredient has no irritation to the skin, it may be blended with cosmetic, it prevents skin irritations of lips and chapped skin, is expected to have soft feeling in use, to make people undergo rejuvenation, etc. An amount of the active ingredient added is 0.01-20wt% based on the whole amount of pharmaceutical preparation, preferably 0.01-5wt% in the case of cosmetic, and 1-20wt% in the case of quasi-drug.
Medical Rate Control aimed at ventricular rate target of 90 beats per minute. Specific medical therapy to be determined for each patient by individual clinician.
The other side face received SVF-gel filling. The autologous fat graft was harvested from the lower abdomen or inner thigh of all subjects. The Coleman fat was was islolated by centrifugation. Then, SVF gel further islolated by using cutting and centrifugation. 22G sharp-tip injector was used to inject the SVF-gel into the dermis of acne scars.
This is a single center, single-arm, open-label, phase II study to investigate the efficacy and toxicities of total neoadjuvant therapy in patients with middle or lower rectal cancer. This study is planned to start after the approval by IRB, enroll patients for 2 years, and follow the clinical outcome for another 5 years. It will be conducted at National Cheng Kung University Hospital. Forty-two subjects will be enrolled. Patients who have newly diagnosed stage II or III, middle or low rectal adenocarcinoma will be recruited to receive the TNT treatment. The TNT includes the short-course radiotherapy (5×5 Gy over a maximum of 8 days)) followed by chemotherapy with the regimen of mFOLFOX6 for total 9 cycles
Certain embodiments described herein relate to optical sensors, systems, and methods for continuous glucose monitoring. In some embodiments, methods of making layered optical sensors are disclosed. The optical sensor may be formed by laminating a plurality of sheets together to form a final sensor. In some embodiments, the sensor tip comprises an oxygen conduit, an enzymatic layer, and a sensing layer. In some embodiments, the sensor includes a plurality of waveguides configured to direct light to and from a target material, such as an oxygen sensing polymer. Systems are also disclosed relating to an adhesive system for attaching an optical sensor-transmitter system. Methods and systems relating to the sensor inserter system are also disclosed. The inserter may include a lancet tip including a convex feature attached to a first surface of the lancet tip.
Tolterodine tartrate (TTD) was the first antimuscarinic medication developed exclusively for the treatment of overactive bladder syndrome and was approved by the FDA in 1998. As a result of the drug's extensive utilization within the local community following its authorization, there is a pressing need to develop and validate a spectrofluorometric method that is economically efficient, easily reproducible, environmentally sustainable, and possesses high sensitivity. The developed approach relies on enhancing the fluorescence intensity of TTD to reach a level 720 % higher than its initial value, achieved through the application of an aqueous sodium dodecyl sulfate (SDS) solution. A strong correlation was observed with a correlation coefficient of 0.9998 between the concentration of TTD and the fluorescence intensity within the range of 25.0-500.0 ng mL-1. This approach could be employed to quantify TTD in its pure form and to examine pharmaceutical tablets for the purposes of verifying uniform content. Additionally, it was utilized for the evaluation of TTD concentrations in spiked human plasma.
A method of generating a user interface for use in documenting a patient encounter comprises: automatically identifying, with a computing device, at least one documentation protocol based on at least one element of the patient's medical record; and generating a user interface including at least one of the identified documentation protocols, the at least one identified documentation protocols identifying at least one medical finding. A system comprises a data store encoded on a memory device, the data store comprising documentation protocols. The system further comprises an input apparatus. A computing device is in data communication with the data store and the input apparatus. The computing device is programmed to receive findings input through the input apparatus, identify a documentation protocol based on the finding input through the input apparatus, and generate a user interface. The user interface comprising the identified documentation protocol.
<P>PROBLEM TO BE SOLVED: To provide a system and user interface which integrates and processes event-associated messages affecting healthcare delivered to a patient and supports creation, initiation and modification of currently operating workflow processes involving processing of event messages.  <P>SOLUTION: This system for scheduling a set of tasks to be performed by at least one individual to support healthcare delivery employs a method for providing a user interface for processing an event. The event represents a change in circumstances potentially affecting healthcare delivered to a patient. The method involves a step for initiating generation of at least one display image in response to user command. The display image or images support the identification of an event and an associated parameter as well as the designation of a predetermined process associated with the identified event.  <P>COPYRIGHT: (C)2006,JPO&NCIPI
About 90% of nonsmoking people in the US are exposed to ETS. More than 50 chemicals identified in ETS have been found to cause cancer and exposure has been linked to heart disease in adults and SIDS, ear infections and numerous respiratory problems, including asthma in children. In 2007, the Environmental Protection Agency and the Office of Head Start-a national program that provides economically disadvantaged children services to enhance their social and cognitive development-announced a new initiative to promote smoke-free homes for children in Head Start programs. Because Head Start reaches high-risk, low-income preschool children, it offers a timely intervention for reducing children's exposure to ETS. Head Start also attempts to engage parents, which is an important component of reducing household ETS exposure among children. This study will determine the effectiveness of a home-delivered, motivational interviewing-based program in reducing ETS exposure and improving lung health among children who are enrolled in the Baltimore City Head Start program and whose households include a smoker.

Participation in this study will last 1 year. First, all participating families will be visited at home by a study staff person who will attach special filters that will track the amount of nicotine in the various rooms of the house. During this initial visit, the participating children will undergo weight and height measurements and saliva sampling. About a week later, the filters will be collected, a 2nd saliva samples will be taken and parents will be interviewed about their family and child's health. Families will then be randomly assigned to one of two groups. Both groups will received educational information about reducing tobacco smoke exposure. One group will also receive the home-delivered, motivational interviewing-based program aimed to reduce ETS. This program will consist of 2 home visits and 2 phone calls, both led by health counselor who will teach participants how to reduce their child's exposure to tobacco smoke. The home visits will occur during Weeks 1 \& 2 and the phone calls will occur during Weeks 3 \& 6. Follow-up visits for all participating families will occur at Months 3,6 and 12 and will involve repeat filter testing, saliva monitoring and interviews.
A clinical trial matching apparatus according to an embodiment includes processing circuitry. The processing circuitry receives patient information. The processing circuitry retrieves a clinical trial matching the patient from clinical trials based on the patient information, by referring to storage circuitry that stores data for associating a clinical trial in which medication conditions are set with the results of the clinical trial, for the clinical trials. The processing circuitry presents the retrieved clinical trial. The processing circuitry collects, and stores in the storage circuitry, the results obtained by conducting the retrieved clinical trial on the patient and patient's clinical information. The processing circuitry updates the conditions of the retrieved clinical trial based on the clinical information, when there is clinical information that can identify a significant difference in drug efficacy in the collected clinical information.
A fast-track program is an evidence-based, multimodal approach for patients undergoing surgery to reduce perioperative morbidity, hospital stay and cost and to increase patient centered well-being. Particularly in visceral surgery of the colon it is gaining widespread acceptance (Schwenk 2009). Optimized pain relief is a core component of any fast-track regimen (Kehlet and Wilmore 2008). In this context epidural analgesia has become the standard of care for early postoperative pain therapy (Hasenberg 2009), providing superior pain relief compared to parenteral opioids (Block 2001).

However, it is debated whether non-opioid analgesics should be given as adjuncts when epidural analgesia is already present. Some studies have found reduced pain using NSAID as adjunct (Scott 1994), leading to a positive recommendation in the German guidelines for postoperative pain therapy (S3-Leitlinie). However, other studies (Mogensen 1992) have not found an effect of non-opioids in addition to epidural analgesia. Further studies are also needed to assess whether nonopioid adjuncts can facilitate the change from epidural to systemic analgesia (typically on the 2nd or 3rd postoperative day) and reduce opioid consumption during the days after catheter removal.

Fast-track surgery is a multi-model process, and every step in this process needs to be fine-tuned to yield best results (Langelotz 2005). Until now studies have compared only groups with either epidural or systemic analgesia, but for optimal recovery a sequential approach with a combination of both is probably a better choice. A typical multimodal analgesia regimen after removal of an epidural at our institution consists of acetaminophen and ibuprofen. Opioids are avoided if possible, but are added if needed. An improved non-opioid analgesia regimen is a sought-after goal in this fast-track-phase. The study is controlled in terms of the type of surgery (laparoscopic colon and rectal surgery) and all factors of the multimodal analgesia treatment.
OBJECTIVE: To investigate the correlation between oxygen saturation index (OSI) and oxygenation index (OI) for evaluating the blood oxygenation status in neonates with respiratory failure requiring mechanical ventilation support and to assess the predictive capability of OSI in determining clinically relevant OI cutoffs.
METHODS: A prospective study was conducted on neonates who received invasive mechanical ventilation at the neonatal intensive care unit of tertiary hospital in Vietnam. Bland-Altman analysis was utilized to evaluate the agreement between OSI and OI.
RESULTS: A total of 123 neonates, including both term and preterm infants, were included in the study. A high agreement rate of 94.3% within the 95% limits of agreement (between OI and OSI), with a narrow similarity value of 3.3 (95% CI: -5.1 to 11.8) and high correlation coefficient (r = 0.791, p<0.001) was observed. The OSI cut-off value for predicting an OI of >15 was determined to be 7.45, with a sensitivity of 100% and a specificity of 87.4% (AUC 0.955; 95% CI: 0.922-0.989, p < 0.05). Similarly, an OSI cutoff value of 9.9 corresponded to an OI of 25, displaying a sensitivity of 100% and specificity of 87.4% (AUC 0.92). The receiver operating characteristic (ROC) curves for OSI exhibited statistically significant results (p < 0.05).
CONCLUSION: The findings demonstrate a strong correlation between OSI and OI in neonates with respiratory failure. Furthermore, OSI, as a non-invasive method, can serve as a substitute for OI to evaluate the severity of hypoxic respiratory failure and lung injury in neonates.
NEW MATERIAL:A fibronectin physiologically active substance complex. EXAMPLE:Fibronectin daunomycin complex. USE:An antitumor agent, antibacterial agent, and anti-inflammatory agent. Since fibronectin is specifically collected in disease sites such as wound site, inflammatory site, new site of propagation of organism cell, etc., it is used as a carrier, and linked to a physiologically active substance useful for remedy of various kinds of diseases, to give a drug having high affinity for affected site. A smaller dose of the complex has sufficient effect than a dose of the physiologically active substance itself. PROCESS:Fibronectin is blended and reacted with a protein crosslinking agent (e.g., glutaraldehyde, carbodiimide, etc.) and a physiologically active substance (e.g., daunomycin, cefalothin, etc.), to give the titled complex. The reaction is preferably carried out in a buffer solution at room temperature.
FIELD: medicine, immunology, diagnostics. SUBSTANCE: diagnostics is conducted by registering the results of agglutination reaction of carrier particles suspension sensitized by diphtheritic antitoxin together with a material tested for the presence of diphtheritic toxin. Blood serum is used as a tested material. Monodispersible latex at 0.7-1.9 mcm size of particles was used as dispersion of carrier particles. Agglutination reaction is applied in a drop upon a slide. Registration of results is conducted in 3-10 minutes after mixing reagents and in an hour after material sampling to make analysis either for the presence or absence of agglutinates observed visually. In case of positive results of reaction it is possible to state upon a toxic type of diphtheritic infection. EFFECT: higher efficiency and informativity of the method to provide prediction just in an hour after blood sampling for further analysis. 2 tbl
A purpose of the present invention is to provide a novel diagnosis and risk evaluation method for cancer brain metastasis and a novel treatment and prevention method therefor by clarifying the mechanism of blood-brain barrier (BBB) disruption in brain metastasis. Another purpose of the present invention is to provide a novel drug delivery system to the brain. Still another purpose of the present invention is to provide a medicine, composition and kit to be used in these methods. Therefore, the present invention relates to a method for diagnosing brain metastasis or evaluating the risk of the occurrence of brain metastasis, said method comprising determining miR-181c level in a specimen. Further, the present invention relates to a method for treating or preventing brain metastasis, said method comprising inhibiting the expression or activity of miR-181c in a cancer patient. Furthermore, the present invention relates to a method for improving permeability through BBB with the use of miR-181c or PDPK1 and a method for enabling a desired active ingredient to pass through BBB and reach inside the brain.
A functional food ingredient designed to inhibit cholesterol absorption. ACP is a freeze dried defatted egg powder containing specific Anti-NPCIL1 (Niemann-Pick C1-like 1) IgY. NPC1L1 is known as a biological target of the cholesterol-uptake inhibitor, Ezetimibe.
<P>PROBLEM TO BE SOLVED: To prepare a cosmetic for the softening treatment of the hair, free from a surfactant.  <P>SOLUTION: This cosmetic for the softening treatment of the hair contains 5-20 mass% clay mineral. Preferably, the clay mineral is mica. More preferably, the mica contains two kinds of aluminum fluoromagnesium sodium silicate and aluminum fluoromagnesium potassium silicate. The cosmetic preferably contains an oily component as a softening component, and the content of the oily component is preferably 1-20 mass%. The oily component is preferably a silicone.  <P>COPYRIGHT: (C)2005,JPO&NCIPI
New galenic form of trinitroglycerin for percutaneous application comprises a pliable support film covered by a layer of a microporous polymer having a lacuneous structure in which the lacuna are occupied by the trinitroglycerin. The support is applied to the skin so as to allow the trinitroglycerin to diffuse across the micropores, diffuse from the polymer and penetrate the epidermis. The new galenic form allows a prolonged effect. Activity tests are described. Pref. microporous polymer is cellulose triacetate in the form of a film, microchips or fibres. The polymer is pref. deacidified and contains 0.1- 5 mg. pref. 0.5-1 mg of trinitroglycerin per cm2 of active surface.
The androgen receptor (AR) is the key driver of prostate differentiation and prostate cancer (PC) progression, and androgen ablation is the cornerstone of advanced PC treatment. Prostate-specific membrane antigen (PSMA) represents another target of interest in PC. Previous publications have reported inconsistent associations between androgen levels and PSMA expression. Using a panel of prototypical human PC cell lines, this relationship is clarified. PSMA is a biomarker that distinguishes AR-positive/PSMA-positive adenocarcinomas from AR- negative variants. PSMA is a cell surface barometer of androgen activity that can be readily identified by immunohistochemistry and/or in vivo imaging. Given that anti-androgen therapy is likely to remain a cornerstone of PC treatment, the associated up-regulation of PSMA, as well as its other characteristics, makes it a compelling target opportunity in PC.
Low income, Mexican American patients with diabetes exhibit high rates of medication nonadherence, which results in poor blood sugar control and serious complications, and often have difficulty communicating their concerns about the medication regimen to physicians. Interventions led by community health workers (CHWs), non-professional community members who are trained to work with patients to improve engagement and communication during the medical visit, have had mixed success in improving outcomes. Although CHWs possess excellent cultural competency and are very effective at establishing rapport with patients, they often lack a sophisticated understanding of all the potential challenges that can come with following a regimen. The primary objective of this project is to develop and pilot test a prototype software toolkit called "EMPATHy" that a CHW can administer to help patients identify and articulate the most important barriers to adherence that they face.

The EMPATHy toolkit will be piloted in an ongoing intervention (Coached Care) in which CHWs are trained to be "Coaches" to meet with patients before the medical visit, and help them prepare a list of important questions for the doctor. The Lead Researcher (Billimek) is a co-director of this intervention program at UCI's Ambulatory Clinics, including the Family Health Center in Santa Ana ,with a highly vulnerable population-low income Mexican American patients with diabetes and a history of nonadherence. A CHW will be trained to use two commercially available software programs configured by the PI to deliver the intervention materials. Patients participating in Coached Care (which is a clinic- based intervention, not a research protocol) will be recruited to (1) complete a Coached Care intervention session that has been modified to incorporate the EMPATHy Toolkit, (2) answer questions about barriers to medication adherence and the feasibility/usability of the software (3) allow the research team to abstract data on the medication regimen and diabetes outcomes (hemoglobin A1c, LDL cholesterol, etc) from the patient's medical record.
BACKGROUND: Tracheal agenesis, or tracheal atresia, is a rare congenital anomaly. The presence of a tracheoesophageal fistula (TEF) can help with breathing for newborns with tracheal agenesis. In this article, we presented three unique cases and outcomes of neonates with tracheal agenesis along with a review of the literature.
METHODS: This study consisted of a single center case series followed by a review of literature. Case reports were generated using both written and electronic medical records from a single hospital. We summarized three unique cases and outcomes of neonates with tracheal agenesis and performed a review of the literature.
RESULTS: We identified three cases of tracheal agenesis presented with severe cyanosis without spontaneous crying upon birth. Experienced pediatricians attempted to intubate the babies but were unsuccessful. Endotracheal tubes were subsequently either accidentally or purposely placed into the esophagus, and oxygen saturation levels improved. This suggested tracheal agenesis with TEF. Two cases underwent surgical intervention after resuscitation with esophageal intubation.
CONCLUSION: Esophageal intubation may be a life-sustaining ventilation support for patients with tracheal agenesis and TEF at initial resuscitation. Clinicians should suspect tracheal agenesis when a newborn presents with severe cyanosis and voiceless crying upon birth, and esophageal intubation should be immediately attempted.
This Arm will receive a remote intervention (via videacalls) based on motivational interviewing to improve self-care. The intervention will be delivered seven time over 12 months.